UNSPSC 51111758: Panitumumab

This classification denotes a monoclonal antibody with the molecular formula C6398H9878N1694O2016S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6A901E312A, more generally known as panitumumab. European Medicines Agency schedules panitumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25390. The term PANITUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.

Most nations schedule Panitumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, PANITUMUMAB remains the US FDA Preferred Term for this commodity.. Panitumumab bears US NLM identifiers UMLS ID C0879427 and NCI Concept Code C1857.

UNSPSC 51111758 Panitumumab is a Commodity code that nominally designates a specific monoclonal antibody pharmaceutical, but recent state and local procurement activity under this code does not align with that scope. The four recent opportunities posted under this code span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). The source shows no procurement activity for panitumumab itself, indicating that either the code has been misapplied to broader pharmaceutical and medical supply solicitations, or the code's recent state and local activity does not reflect its intended commodity scope.

The issuing bodies include county governments (Seminole County), state health agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances (MMCAP). Recent opportunities span Florida, Texas, Minnesota, and Oregon, with activity concentrated in the first half of 2026. The City of Tampa's IFB for medical and first aid supplies (Bid 26P00145, due March 13, 2026) targets an estimated $700,000 contract and is restricted to certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) establishes multi-award contracts effective July 1, 2026, through authorized wholesalers with a 3 percent administrative fee structure. The Texas Health and Human Services Commission's RFI (HHS0017013, April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. Given the mismatch between the code's nominal scope and actual procurement activity, treat this code as unreliable for panitumumab-specific opportunities.